NCT04136535View on ClinicalTrials.gov

Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC

PHASE2RecruitingINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

November 18, 2021

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
NSCLC Stage IV
Interventions
DRUG

Pemetrexed

Pemetrexed，500mg/m²，ivgtt ，d1，q3w

DRUG

Carboplatin

Carboplatin，AUC 5.0，ivgtt，d1，q3w，

DRUG

Anlotinib

Anlotinib ，12 mg，po，qd，d1-14，q3w；

Trial Locations (1)

518116

RECRUITING

Caner hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Uninon Medical college, Shenzhen

All Listed Sponsors
lead

Fudan University

OTHER